[(18)F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

BACKGROUND: Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [(18)F]FDG PET radiomics signature (iRADIOMICS) predicts resp...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Radiol Oncol
Autors principals: Valentinuzzi, Damijan, Vrankar, Martina, Boc, Nina, Ahac, Valentina, Zupancic, Ziga, Unk, Mojca, Skalic, Katja, Zagar, Ivana, Studen, Andrej, Simoncic, Urban, Eickhoff, Jens, Jeraj, Robert
Format: Artigo
Idioma:Inglês
Publicat: Sciendo 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7409607/
https://ncbi.nlm.nih.gov/pubmed/32726293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2020-0042
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars